MediGene sells full European rights for Eligard® to Astellas for EUR 25 million and ongoing royalties
. - Astellas to make oneofff payments totaling EUR 25 million - MediGene to remain entitled to royalties - No furth…
. - Astellas to make oneofff payments totaling EUR 25 million - MediGene to remain entitled to royalties - No furth…
The biotech company MediGene AG (Frankfurt, Prime Standard, TecDAX) announces that MediGene, Inc., its wholly owned subs…
Today MediGene AG (Frankfurt, Prime Standard: MDG) presented the detailed efficacy data of the company's drug candidate…